A Retrospective Review of the Medical Management of Hypertension and Diabetes Mellitus Following Sleeve Gastrectomy

Tritsch, Adam; Bland, Christopher M.; Hatzigeorgiou, Christos; Sweeney, Lori B.; Phillips, Michael

doi:10.1007/s11695-014-1375-y

Cited by 21 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same study also observed a reduction in antihypertensive medication use. 23 This supports what was observed in the present study, since there was a reduction in obesity-related comorbidities and in medication use 6 months after the bariatric surgery.…”

Section: Discussionsupporting

confidence: 93%

Perfil farmacoterapêutico de pacientes obesos no pós-operatório de cirurgia bariátrica

et al. 2016

View full text Add to dashboard Cite

Background: Obesity can be associated with diseases such as diabetes, arterial hypertension and dyslipidemia. Bariatric surgery is one of the most effective treatments available, reducing both weight and comorbidities. Objective: To evaluate the metabolic and pharmacotherapeutic profile of obese patients after bariatric surgery. Methods: This is a retrospective, cross-sectional, observational study conducted at a hospital located in the city of Porto Alegre, RS, Brazil, based on analysis of the medical records for 70 patients who underwent bariatric surgery covering periods spanning from 2 months prior to more than 6 months after their bariatric surgery. Statistical analysis was conducted using SPSS 17.0  . Results: Initial arterial blood pressure was 130/85 mmHg, 6 months after surgery it was 120/80 mmHg (p < 0.01). The metabolic profile 2 months before surgery was as follows: HDL was 34 mg/dL, total cholesterol was 195.07 ± 40.17 mg/dL, LDL was 118.22 ± 41.28 mg/dL, triglycerides were 141.09 ± 43.39 mg/dL, and fasting glycemia was 90 mg/dL. The same figures 6 months after surgery were 43 mg/dL, 133.67 ± 28.14 mg/dL, 65.53 ± 24.3 mg/dL, 104.41 ± 29.6 mg/dL, and 77 mg/dL, respectively (p < 0.01). Use of medications 2 months before surgery was as follows: 41% were on antihypertensives, 39% on hypolipidemics, 10% on oral hypoglycemics, and 97% were on nutritional supplements. These percentages 6 months after surgery had changed to 21%, 19%, 9% and 99%, respectively. Conclusions: This study illustrates that bariatric surgery for obese patients with comorbidities was successful, demonstrating improvements in their metabolic profile and reductions in use of medications used to treat comorbidities.

show abstract

Section: Discussionsupporting

confidence: 93%

Perfil farmacoterapêutico de pacientes obesos no pós-operatório de cirurgia bariátrica

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The resolution rate of T2DM one year after surgery was so effective in patients submitted to VSG as it was in patients undergoing RYGBP 12 . Medications for hypertension and T2DM were reduced or removed from the patient after surgery, before hospital discharge 31 . The same result was obtained by Ching et al 11 with 60% remission rate for T2DM.…”

Section: Resultsmentioning

confidence: 99%

The Role of the Sleeve Gastrectomy and the Management of Type 2 Diabetes

Fuchs¹,

Loureiro²,

Both

et al. 2017

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background : Currently, bariatric surgery has promoted weight loss and improved glycemic control in obese patients through different techniques, including vertical sleeve gastrectomy. Aim : Present and update the different vertical sleeve gastrectomy ways of action, both in the treatment of obesity and diabetes, approaching its potential effect on gastrointestinal physiology, as well as the benefits achieved by this manipulation. Methods : Pubmed database search was used crossing the headings: obesity, type 2 diabetes and sleeve gastrectomy. Results : Published data have shown that short-term weight loss tends to be higher in patients undergoing vertical sleeve gastrectomy compared to Roux-en-Y gastric bypass. In relation to glycemic control, the procedure demonstrated remission of diabetes in up to 60% after one year of surgery. After three years, however, differences in remission rate between surgical and clinical group was not observed, questioning the durability of the technical in a long-term. Conclusion : Despite showing good results, both in the weight loss and co-morbidities, conflicting results reinforce the need for more studies to prove the efficiency of the vertical sleeve gastrectomy as well as to understand its action about the molecular mechanisms involved in the disease.

show abstract

“…For those who required insulin therapy, the mean insulin dose 42.1 units decreased to 16.8 units immediately post operation (p < 0.01) which resumed at 1 month. The mean insulin dose was 13.3 units for 6 months [68]. In another prospective study by Dasgupta et al, (2013), 43 obese Indian patients with T2DM who received LSG were followed up for 12-month.…”

Section: Short-term Effects Of Lsgmentioning

confidence: 99%

Resolving of diabetes mellitus post laparoscopic sleeve gastrectomy

Arrowaili¹

2017

IJMDC

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally with obesity as a risk factor for T2DM. Non-surgical and surgical methods are used to treat morbid obesity. Laparoscopic Sleeve Gastrectomy (LSG) is being recognized as an effective independent procedure for treating morbidly obese patients with T2DM by removing the gastric fundus and transforming the stomach into a narrow gastric tube. This paper discusses effects of LSG in T2DM resolution and remission, and its short-term and long-term influence on obese patients with T2DM with making comparison with other types of surgeries to resolve T2DM. LSG seems to have a substantial beneficial influence on T2DM, producing resolution in the majority of patients included in the studies. LSG has gained popularity for its relative operative ease and lower risk profile.

show abstract

A Retrospective Review of the Medical Management of Hypertension and Diabetes Mellitus Following Sleeve Gastrectomy

Abstract: Medication adjustments for HTN and T2DM made immediately in the postoperative period following SG persisted throughout the 6-month follow-up period and in some patients, required further adjustments.

Cited by 21 publications

References 10 publications

Perfil farmacoterapêutico de pacientes obesos no pós-operatório de cirurgia bariátrica

Perfil farmacoterapêutico de pacientes obesos no pós-operatório de cirurgia bariátrica

The Role of the Sleeve Gastrectomy and the Management of Type 2 Diabetes

Resolving of diabetes mellitus post laparoscopic sleeve gastrectomy

Contact Info

Product

Resources

About